ADMA Biologics Inc shares trade up 3.07 percent after positive clinical and regulatory developments bolster investor confidence.
Click Here for a Millionaire's POV on Trading ADMA
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- Mizuho cut its price target on ADMA Biologics from $30 to $24 but kept an Outperform rating, signaling still‑bullish stance but more cautious expectations ahead of Q1 earnings.
- Cantor Fitzgerald downgraded the stock from overweight to neutral, driving a roughly 19% drop on very heavy volume and setting off a sharp momentum selloff.
- Shares fell about 13–20% over 2026/03/25–2026/03/26, with intraday levels near $9.90, $8.10, and $7.71, turning the name into a high‑volatility trading vehicle.
- Management issued a detailed rebuttal to Culper Research’s short report, supplying distributor, inventory, demand, and audit data that pointed to strong ASCENIV and BIVIGAM demand and clean 2024–2025 audits.
- After this rebuttal, the stock ripped higher, with gains of more than 10–21% intraday as traders reassessed ASCENIV’s demand, pricing power, and the credibility of the short thesis.
Weekly Update Apr 13 – Apr 17, 2026: On Friday, April 17, 2026 ADMA Biologics Inc stock [NASDAQ: ADMA] is trending up by 3.07%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – positive
ADMA now sits as a scaled, profitable IVIG player with best‑in‑class growth and attractive economics versus small‑mid cap biotech. Revenue of ~$510M with 3‑ and 5‑year CAGRs of 49% and 65% underscores durable demand, while gross margin of 57% and EBIT margin above 37% reflect strong pricing power and manufacturing leverage. ROIC above 50% and ROE mid‑30s are elite for the group. Balance sheet risk is low (D/E 0.17, current ratio 6.7), and Q4 free cash flow of ~$34M confirms a self‑funding model.
Technically, ADMA is in a short‑term momentum uptrend, with successive higher closes from ~$10.45 to ~$10.95 over the last five sessions and a clear breakout candle on 4/16–4/17. Five‑minute tapes show aggressive dip‑buying near $10.40–10.50 and strong closing demand above $10.90, likely driven by short covering and fundamental buyers. The actionable level is $10.40: above it, risk‑on long bias; a decisive break below signals a failed breakout and a move back toward $9.75–10.00.
More Breaking News
- CRDO Stock Surges As DustPhotonics Deal Supercharges AI Story
- RXT Stock In Focus As Debt Warnings Collide With Contract Wins
- MHK Stock Steadies After Evercore Slashes Price Target
- ROLR Stock Volatility Draws Active Day Traders
The recent short‑seller attack and subsequent sharp drop were fully met by a detailed rebuttal, heavy‑volume reversal, and reaffirmation of ASCENIV demand, validating fundamentals and reducing governance overhang. Sector‑wise, ADMA is materially outgrowing healthcare and biotech benchmarks and trades at a reasonable ~18x earnings and ~5x sales given its margins and ROIC. With Mizuho still at Outperform and target trimmed to $24, I see fair value in the $18–20 range over 12–18 months, with support at $9.75 and resistance near $12.50.
Quick Financial Overview
ADMA Biologics Inc sits in an unusual spot for a mid‑cap biotech name: strong profitability metrics alongside high volatility. Revenue is about $510.2M, with three‑ and five‑year growth rates of 49.05% and 64.6%, showing a clear expansion trend. Gross margin of 57.4% and EBIT margin of 37.2% point to solid pricing power and operating efficiency, while a profit margin near 28.8% keeps the bottom line healthy for now.
On valuation, ADMA Biologics Inc trades around 17.75 times earnings and at roughly 4.97 times sales, with price to free cash at 17.8. Those multiples are not cheap, but they line up with a fast‑growing, profitable specialty pharma story. The balance sheet backs that up: total debt to equity of 0.17, long‑term debt to capital of 0.14, and a current ratio of 6.7 indicate ample liquidity and modest leverage, key supports during volatility spikes.
Price action confirms that traders treat ADMA as a catalyst name. The recent weekly tape shows a push from roughly $10.38 toward $10.95, with a breakout attempt above $11.00. Intraday, the 5‑minute chart clusters most prints between $10.85 and $11.00, with repeated dips bought near $10.90 and sellers stepping in just over $11.00. That builds a tight intraday range, suggesting short‑term balance after the violent March swings, and sets up clear reference levels for day traders.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.